Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbott, Galapagos In Autoimmune Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Abbott, Galapagos In Autoimmune Pact

Galapagos is eligible to receive milestone payments totaling $1.0 billion

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott and Galapagos have entered into a global collaborationto develop and commercialize an oral, next-generation JAK1 inhibitor for the potential treatment of multiple autoimmune diseases. GLPG0634 is a highly selective JAK1 inhibitor in Phase II development for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases. Results from a recent Phase IIa study of GLPG0634 demonstrated positive efficacy measures in RA. An additional Phase IIa dose-range finding study is expected to begin soon.
 
Abbott will make an initial upfront payment of $150 million for rights related to the global collaboration. Upon successful completion of the RA Phase II studies, Abbott will license the program for a one-time fee of $200 million. Abbott will assume responsibility for Phase III development and global manufacturing. Pending certain developmental, regulatory, commercial and sales milestones, Galapagos is eligible to receive additional milestone payments totaling $1.0 billion, in addition to royalties on sales. Galapagos retains co-promotion rights in Belgium, the Netherlands and Luxembourg.
 
“This collaboration with Abbott, the global leader in autoimmune diseases, is a great recognition of the value of GLPG0634. We view Abbott to be the best partner possible to deliver a complete clinical program and a powerful market introduction. We are excited to continue the Phase II trials and expect to deliver to Abbott a complete Phase II package in 2014,” said Onno van de Stolpe, chief executive officer, Galapagos.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics